Intra-Cellular Therapies Crecimiento futuro
Future controles de criterios 6/6
Intra-Cellular Therapies se prevé un crecimiento anual de los beneficios y los ingresos de 56% y 28.3% respectivamente. Se prevé que el BPA sea de grow en 55.4% al año. Se prevé que la rentabilidad de los fondos propios sea de 33.2% en 3 años.
Información clave
56.9%
Tasa de crecimiento de los beneficios
56.2%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 20.8% |
Tasa de crecimiento de los ingresos | 27.2% |
Rentabilidad financiera futura | 27.4% |
Cobertura de analistas | Good |
Última actualización | 11 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Dec 24Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment
Dec 21Intra-Cellular Therapies: A Leader In The Psychiatric Medicine Space
Nov 08We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Aug 06We Think The Compensation For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Looks About Right
Jun 15Intra-Cellular Therapies (ITCI) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow
Jun 04FDA accepts Intra-Cellular Therapies' lumateperone applications for bipolar depression
May 03Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 1,280 | 370 | 530 | 483 | 12 |
12/31/2025 | 920 | 114 | 202 | 183 | 17 |
12/31/2024 | 659 | -62 | -41 | -7 | 17 |
12/31/2023 | 464 | -140 | -124 | -124 | N/A |
9/30/2023 | 420 | -155 | -162 | -161 | N/A |
6/30/2023 | 366 | -184 | -190 | -189 | N/A |
3/31/2023 | 311 | -228 | -248 | -247 | N/A |
12/31/2022 | 250 | -256 | -271 | -270 | N/A |
9/30/2022 | 188 | -298 | -305 | -304 | N/A |
6/30/2022 | 138 | -321 | -331 | -330 | N/A |
3/31/2022 | 103 | -304 | -296 | -295 | N/A |
12/31/2021 | 84 | -284 | -260 | -260 | N/A |
9/30/2021 | 71 | -259 | -255 | -255 | N/A |
6/30/2021 | 56 | -237 | -239 | -239 | N/A |
3/31/2021 | 38 | -232 | -227 | -227 | N/A |
12/31/2020 | 23 | -227 | -230 | -230 | N/A |
9/30/2020 | 10 | -207 | -196 | -197 | N/A |
6/30/2020 | 3 | -187 | -163 | -163 | N/A |
3/31/2020 | 1 | -160 | -144 | -144 | N/A |
12/31/2019 | 0 | -148 | -129 | -128 | N/A |
9/30/2019 | N/A | -148 | -123 | -122 | N/A |
6/30/2019 | N/A | -155 | -122 | -121 | N/A |
3/31/2019 | N/A | -154 | -127 | -127 | N/A |
12/31/2018 | N/A | -155 | -119 | -118 | N/A |
9/30/2018 | 0 | -145 | -115 | -114 | N/A |
6/30/2018 | 0 | -126 | -101 | -100 | N/A |
3/31/2018 | 0 | -106 | -92 | -91 | N/A |
12/31/2017 | 0 | -98 | -81 | -80 | N/A |
9/30/2017 | 0 | -95 | N/A | -84 | N/A |
6/30/2017 | 0 | -102 | N/A | -99 | N/A |
3/31/2017 | 0 | -116 | N/A | -88 | N/A |
12/31/2016 | 0 | -116 | N/A | -91 | N/A |
9/30/2016 | 0 | -118 | N/A | -98 | N/A |
6/30/2016 | 0 | -120 | N/A | -89 | N/A |
3/31/2016 | 0 | -110 | N/A | -106 | N/A |
12/31/2015 | 0 | -105 | N/A | -102 | N/A |
9/30/2015 | 0 | -91 | N/A | -73 | N/A |
6/30/2015 | 0 | -65 | N/A | -57 | N/A |
3/31/2015 | 0 | -48 | N/A | -32 | N/A |
12/31/2014 | 1 | -31 | N/A | -23 | N/A |
9/30/2014 | 1 | -24 | N/A | -25 | N/A |
6/30/2014 | 2 | -22 | N/A | -26 | N/A |
3/31/2014 | 2 | -26 | N/A | -27 | N/A |
12/31/2013 | 3 | -27 | N/A | -23 | N/A |
9/30/2013 | 3 | -20 | N/A | -18 | N/A |
6/30/2013 | 2 | -17 | N/A | -19 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: ITCI se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).
Beneficios frente mercado: ITCI se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: ITCI se espera que sea rentable en los próximos 3 años.
Ingresos vs. Mercado: ITCISe prevé que los ingresos de la empresa (28.3% al año) crezcan más deprisa que los del mercado US (8.1% al año).
Ingresos de alto crecimiento: ITCISe prevé que los ingresos de la empresa (32.3% al año) crezcan más deprisa que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: ITCIse prevé que la Rentabilidad de los fondos propios sea alta dentro de 3 años (31.1%)